Annexin A5 as a new potential biomarker for cisplatin-induced toxicity in human kidney epithelial cells

Biomolecules and Therapeutics

Volumn 21, Issue 3, 2013, Pages 190-195

  Kwon, Yeo Jung ^a   Jung, Jin Joo ^a   Park, Na Hee ^a   Ye, Dong Jin ^a   Kim, Donghak ^b   Moon, Aree ^c   Chun, Young Jin ^a  

^a Chung Ang University   (South Korea)

^b Konkuk University   (South Korea)

^c Duksung Women's University   (South Korea)

Author keywords

Annexin A5; Biomarker; Cisplatin; Nephrotoxicity; Proteomic analysis

Indexed keywords

BIOLOGICAL MARKER; CISPLATIN; LIPOCORTIN 5; MESSENGER RNA;

ARTICLE; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; GENE EXPRESSION; HUMAN; HUMAN CELL; KIDNEY CELL; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MICROARRAY ANALYSIS; NEPHROTOXICITY; PROTEIN ANALYSIS; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TWO DIMENSIONAL GEL ELECTROPHORESIS; WESTERN BLOTTING;

EID: 84878455468     PISSN: 19769148     EISSN: 20054483     Source Type: Journal    
DOI: 10.4062/biomolther.2013.026     Document Type: Article

References (31)

1. Damia, G., Filiberti, L., Vikhanskaya, F., Carrassa, L., Taya, Y., D'Incalci, M. and Broggini, M. (2001) Cisplatinum and taxol induce different patterns of p53 phosphorylation. Neoplasia 3, 10-16.
2. Devarajan, P. (2007) Neutrophil gelatinase-associated lipocalin: new paths for an old shuttle. Cancer Ther. 5, 463-470.
3. Donzelli, E., Carfi, M., Miloso, M., Strada, A., Galbiati, S., Bayssas, M., Griffon-Etienne, G., Cavaletti, G., Petruccioli, M. G. and Tredici, G. (2004) Neurotoxicity of platinum compounds: comparison of the effects of cisplatin and oxaliplatin on the human neuroblastoma cell line SH-SY5Y. J. Neurooncol. 67, 65-73.
4. Dreier, R., Schmid, K. W., Gerke, V. and Riehemann, K. (1998) Differential expression of annexins I, II and IV in human tissues: an immunohistochemical study. Histochem. Cell Biol. 110, 137-148.
5. Ea, H. K., Monceau, V., Camors, E., Cohen-Solal, M., Charlemagne, D. and Liote, F. (2008) Annexin 5 overexpression increased articular chondrocyte apoptosis induced by basic calcium phosphate crystals. Ann. Rheum. Dis. 67, 1617-1625.
6. Fernandez, J., Gharahdaghi, F. and Mische, S. M. (1998) Routine identifi cation of proteins from sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) gels or polyvinyl difl uoride membranes using matrix assisted laser desorption/ionization-time of fl ight-mass spectrometry (MALDI-TOF-MS). Electrophoresis 19, 1036-1045.
7. Franke, R. M., Kosloske, A. M., Lancaster, C. S., Filipski, K. K., Hu, C., Zolk, O., Mathijssen, R. H. and Sparreboom, A. (2010) Infl uence of Oct1/Oct2-defi ciency on cisplatin-induced changes in urinary Nacetyl- beta-D-glucosaminidase. Clin. Cancer. Res. 16, 4198-4206.
8. Hanigan, M. H. and Devarajan, P. (2003) Cisplatin nephrotoxicity: molecular mechanisms. Cancer Ther. 1, 47-61.
9. Harmers, F. P., Gispen, W. H. and Neijt, J. P. (1991) Neurotoxic sideeffects of cisplatin. Eur. J. Cancer 27, 372-376.
10. Kenis, H., Hofstra, L. and Reutelingsperger, C. P. (2007) Annexin A5: shifting from a diagnostic towards a therapeutic realm. Cell. Mol. Life Sci. 64, 2859-2862.
11. Kenis, H., van Genderen, H., Bennaghmouch, A., Rinia, H. A., Frederik, P., Narula, J., Hofstra, L. and Reutelingsperger, C. P. (2004) Cell surface-expressed phosphatidylserine and annexin A5 open a novel portal of cell entry. J. Biol. Chem. 279, 52623-52629.
12. Laurell, G. and Jungnelius, U. (1990) High-dose cisplatin treatment: hearing loss and plasma concentrations. Laryngoscope 100, 724-734.
13. Lokich, J. and Anderson, N. (1998) Carboplatin versus cisplatin in solid tumors: an analysis of the literature. Ann. Oncol. 9, 13-21.
14. Markoff, A. and Gerke, V. (2005) Expression and functions of annexins in the kidney. Am. J. Physiol. 289, F949-956.
15. Matsuda, R., Kaneko, N., Horikawa, Y., Chiwaki, F., Shinozaki, M., Abe, S., Yumura, W., Nihei, H. and Ieiri, T. (2000) Measurement of urinary annexin V by ELISA and its signifi cance as a new urinarymarker of kidney disease. Clin. Chim. Acta 298, 29-43.
16. Moss, S. E. and Morgan, R. O. (2004) The annexins. Genome Biol. 5, 219.
17. Pepinsky, R. B., Tizard, R., Mattaliano, R. J., Sinclair, L. K., Miller, G. T., Browning, J. L., Chow, E. P., Burne, C., Huang, K. S., Pratt, D., Wachter, L., Hession, C., Frey, A. Z. and Wallner, B. P. (1988) Five distinct calcium and phospholipid binding proteins share homology with lipocortin I. J. Biol. Chem. 263, 10799-10811.
18. Prestayko, A. W., D'Aoust, J. C., Issell, B. F. and Crooke, S. T. (1979) Cisplatin (cis-diamminedichloroplatinum II). Cancer Treat. Rev. 6, 17-39.
19. Quasthoff, S. and Hartung, H. P. (2002) Chemotherapy-induced peripheral neuropathy. J. Neurol. 249, 9-17.
20. Raynal, P. and Pollard, H. B. (1994) Annexins: the problem of assessing the biological role for a gene family of multifunctional calciumand phospholipid-binding proteins. Biochim. Biophys. Acta 1197, 63-93.
21. Reviakine, I., Bergsma-Schutter, W., Mazeres-Dubut, C., Govorukhina, N. and Brisson, A. (2000) Surface topography of the p3 and p6 annexin V crystal forms determined by atomic force microscopy. J. Struct. Biol. 131, 234-239.
22. Sherman, S. E. and Lippard, S. J. (1987) Structural aspects of platinum anticancer drug-interactions with DNA. Chem. Rev. 87, 1153-1181.
23. Siddik, Z. H. (2003) Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 22, 7265-7279.
24. Treskes, M. and van der Vijgh, W. J. (1993) WR2721 as a modulator of cisplatin- and carboplatin-induced side effects in comparison with other chemoprotective agents: a molecular approach. Cancer Chemother. Pharmacol. 33, 93-106.
25. Ungethum, L., Kenis, H., Nicolaes, G. A., Autin, L., Stoilova-McPhie, S. and Reutelingsperger, C. P. (2011) Engineered annexin A5 variants have impaired cell entry for molecular imaging of apoptosis using pretargeting strategies. J. Biol. Chem. 286, 1903-1910.
26. Van den Eijnde, S. M., Luijsterburg, A. J., Boshart, L., De Zeeuw, C. I., van Dierendonck, J. H., Reutelingsperger, C. P. and Vermeij-Keers, C. (1997) In situ detection of apoptosis during embryogenesis with annexin V: from whole mount to ultrastructure. Cytometry 29, 313-320.
27. Vermes, I., Haanen, C., Steffens-Nakken, H. and Reutelingsperger, C. (1995) A novel assay for apoptosis. Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fl uorescein labelled Annexin V. J. Immunol. Methods 184, 39-51.
28. Wang, E. J., Snyder, R. D., Fielden, M. R., Smith, R. J. and Gu, Y. Z. (2008) Validation of putative genomic biomarkers of nephrotoxicity in rats. Toxicology 246, 91-100.
29. Wang, X., Martindale, J. L. and Holbrook, N. J. (2000) Requirement for ERK activation in cisplatin-induced apoptosis. J. Biol. Chem. 275, 39435-39443.
30. Yamashita, T., Nagano, K., Kanasaki, S., Maeda, Y., Furuya, T., Inoue, M., Nabeshi, H., Yoshikawa, T., Yoshioka, Y., Itoh, N., Abe, Y., Kamada, H., Tsutsumi, Y. and Tsunoda, S. (2012) Annexin A4 is a possible biomarker for cisplatin susceptibility of malignant mesothelioma cells. Biochem. Biophys. Res. Commun. 421, 140-144.
31. Yao, X., Panichpisal, K., Kurtzman, N. and Nugent, K. (2007) Cisplatin nephrotoxicity: a review. Am. J. Med. Sci. 334, 115-124